Jitsubo Co., Ltd. announced that it has executed the joint development and license agreement with a Japanese pharmaceutical company (undisclosed) on JIT-2001 (development code) for a cardiovascular disease.
The CMC development for JIT-2001 has been carried out by Jitsubo, but Jitsubo and its partner will now carry out collaborative development to jointly advance the product to be approved as a generic drug in Japan. Once it has been approved, the partner will market and sell in Japan.
About Jitsubo Co., Ltd.
Jitsubo has a mission to contribute to the well-being of society through innovative peptide therapeutics and is aiming to become a world class R&D-focused pharmaceutical company that provides solutions to patients using its proprietary peptide-related technologies. Our goals are to address unmet medical needs and administer to the sustainable development of medical care. We pursue these objectives through Molecular Hiving (a novel technology to synthesize peptides in high-quality and at lower costs compared to existing methods) and Peptuneâ„¢ (a peptide structure engineering technology that develops focused peptide libraries during drug discovery).
Jitsubo was acquired by the Sosei Group, an international biopharmaceutical drug development company, in December 2014, and enjoys invaluable support in both R&D and global network. For further information, please visit www.jitsubo.com
Jitsubo Contact:
Akinori Mochizuki
Tel：+81-(0)42401-1721
DSPAH Contact: Public Relations
Tel: +81-(0)120-511-022
